Home glucose monitoring frequency should follow your provider's recommendations, with targeted monitoring typically sufficient for those on GLP-1 therapy alone, while more frequent checks are needed when combined with insulin or sulfonylureas (which increase hypoglycemia risk)
Time-to-onset analysis revealed a median latency of 32 days (IQR 7122) for GLP-1 RA-related NAEs, with 45.28% occurring within 30 days of treatment initiation
Coordinate refills so you are not forced to rush through a vial or discard excess
Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study
Amarasinghe, Naina Singh, Adam M
I received an initial auto reply and within six hours, an agent replied and answered my questions thoroughly